CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition Jan 31, 2020 6:00am EST
CytoDyn Appoints Maura Fleming as Vice President, General Counsel and Corporate Secretary Jan 23, 2020 8:00am EST
CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on January 23, 2020 Jan 22, 2020 1:16pm EST
Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC Jan 22, 2020 5:00am EST
CytoDyn Appoints Alan Timmins as New Independent Director and Chair of the Audit Committee Jan 21, 2020 5:00am EST
CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer Jan 13, 2020 5:00am EST
CytoDyn Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials Dec 23, 2019 6:00am EST
